Para leer el articulo entero seguir este enlace
Common High Blood Pressure Treatment Seems to Reduce Risk of Parkinson’s Disease: What Does It Mean for PD Patients?
During the week of February 11, 2008, news media all over the world reported on a study showing that a widely used, FDA-approved high blood pressure medication — a class of drugs known as calcium channel blockers — seems to reduce the risk of Parkinson’s disease. Independently, D. James Surmeier, PhD, professor and chair of the Department of Physiology at the Feinberg School of Medicine and director of the Morris K. Udall Center of Research Excellence for Parkinson’s Disease of Northwestern University, published work last year showing that one such drug, isradipine, protected dopamine neurons from death in an animal model of Parkinson’s disease. In response, MJFF granted Dr. Surmeier a Rapid Response Innovation Award to investigate the effects of isradipine further to help inform eventual clinical testing. To help people with PD place the excitement around calcium channel blockers in perspective, the Foundation spoke to Dr. Surmeier this week about next steps toward determining the potential of these drugs as a treatment for Parkinson’s disease.
Para leer el articulo entero seguir este enlace
No hay comentarios:
Publicar un comentario